Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults

被引:19
作者
Beauchemin, Melissa [1 ,2 ,3 ]
Sung, Lillian [4 ]
Hershman, Dawn L. [2 ]
Weng, Chunhua [5 ]
Dupuis, L. Lee [4 ,6 ]
Schnall, Rebecca [1 ]
机构
[1] Columbia Univ, Sch Nursing, New York, NY 10032 USA
[2] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA
[3] Columbia Univ, Mailman Sch Publ Hlth, 722 W 168th St 7th Floor, New York, NY 10032 USA
[4] Hosp Sick Children, Toronto, ON, Canada
[5] Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA
[6] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
关键词
Cancer; Guideline-concordant care; Implementation science; Pediatric; AYA; CLINICAL-PRACTICE GUIDELINES; ANTIEMETICS AMERICAN SOCIETY; ANTINEOPLASTIC MEDICATION; NURSES USE; ONCOLOGY; PROPHYLAXIS; ADHERENCE; SEVERITY; THERAPY; CINV;
D O I
10.1007/s00520-020-05310-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Prescribing guideline-recommended anti-emetics is an effective strategy to prevent CINV. However, the rate of guideline-concordant care is not well-understood. The purpose of this study was to describe the proportion of pediatric, adolescent, and young adult patients receiving HEC or MEC who received guideline-concordant antiemetic prophylaxis for acute CINV and to identify potential predictors of guideline-concordant antiemetic prophylaxis. Methods Using electronic health record data from 2016 through 2018, a retrospective single-institution cohort study was conducted to investigate how often patients less than 26 years of age receiving moderately or highly emetogenic chemotherapy receive guideline-concordant prophylaxis for acute CINV. Guideline-concordant care was defined according to guidelines from the Pediatric Oncology Group of Ontario for patients < 18 years and the American Society of Clinical Oncology for those >= 18 years. Independent variables included: sex, age, insurance status, race, ethnicity, cancer type, chemotherapy regimen, clinical setting, chemotherapy emetogenicity, and patient location. Predictors of receiving guideline-concordant care were determined using multiple logistic regression. Results Of 180 eligible patients, 65 (36.1%) received guideline-concordant care. In multivariable analysis, being treated in adult oncology setting (aOR 14.3, CI(95)5.3-38.6), with a cisplatin-based regimen (aOR 3.5, CI(95)1.4-9.0), solid tumor diagnosis (aOR 2.2, CI(95)1.0-4.8), and commercial insurance (aOR 2.4, CI(95)1.1-5.2) were associated with significantly higher likelihood of receiving guideline-concordant care. Conclusions Multi-level factors were associated with receiving guideline concordant care for prevention of CINV in children, adolescents, and young adults receiving emetogenic chemotherapy. These findings can inform current efforts to optimize implementation strategies for supportive care guidelines.
引用
收藏
页码:4761 / 4769
页数:9
相关论文
共 43 条
  • [1] The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
    Aapro, M.
    Molassiotis, A.
    Dicato, M.
    Pelaez, I.
    Rodriguez-Lescure, A.
    Pastorelli, D.
    Ma, L.
    Burke, T.
    Gu, A.
    Gascon, P.
    Roila, F.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (08) : 1986 - 1992
  • [2] Agency for Healthcare Research and Quality, 2018, RACE ETHNICITY LANGU
  • [3] [Anonymous], 2011, CLIN PRACTICE GUIDEL, DOI DOI 10.17226/13058
  • [4] Characteristics and Changes of Pediatric Therapeutic Trials under the Best Pharmaceuticals for Children Act
    Avant, Debbie
    Wharton, Gerold T.
    Murphy, Dianne
    [J]. JOURNAL OF PEDIATRICS, 2018, 192 : 8 - 12
  • [5] Baggott C R., 2009, Children's perspectives on symptoms and health related quality of life during cancer chemotherapy
  • [6] Changes in Children's Reports of Symptom Occurrence and Severity During a Course of Myelosuppressive Chemotherapy
    Baggott, Christina
    Dodd, Marylin
    Kennedy, Christine
    Marina, Neyssa
    Matthay, Katherine K.
    Cooper, Bruce A.
    Miaskowski, Christine
    [J]. JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2010, 27 (06) : 307 - 315
  • [7] Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities
    Barone, Amy
    Casey, Denise
    McKee, Amy E.
    Reaman, Gregory
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 (08)
  • [8] Basch E, 2011, J CLIN ONCOL, V29, P4189, DOI [10.1200/JCO.2010.34.4614, 10.1200/JOP.2011.000397]
  • [9] Why don't physicians follow clinical practice guidelines? A framewouk for improvement
    Cabana, MD
    Rand, CS
    Powe, NR
    Wu, AW
    Wilson, MH
    Abboud, PAC
    Rubin, HR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (15): : 1458 - 1465
  • [10] Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients
    Check, Devon K.
    Reeder-Hayes, Katherine E.
    Zullig, Leah L.
    Weinberger, Morris
    Basch, Ethan M.
    Dusetzina, Stacie B.
    [J]. SUPPORTIVE CARE IN CANCER, 2016, 24 (12) : 4839 - 4847